谷歌浏览器插件
订阅小程序
在清言上使用

Community Study of Fixed-Combination Adapalene 0.1% and Benzoyl Peroxide 2.5% in Acne.

Patricia A Troielli, Beatriz Asis, Alcira Bermejo, Mario Bittar, Hugo Cabrera,Carla Castro, Ezequiel Chouela, Andrés Cordero, Roberto Dobrinin, Sergio Escobar, Mirta Fortino,Daniel Galimberti,Gaston Galimberti, Maria Elsa Giovo, Beatriz Gomez, Maria del Carmen Gras, Mónica Ibarra,Viviana Kizlansky, Patricio Martinez Chabbert, Sergio Ramonda

Skinmed(2010)

引用 27|浏览2
暂无评分
摘要
A new fixed-dose combination formulation of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% has shown excellent efficacy and safety in registration studies; however, it can be difficult to judge the real-world performance of a product using only the results from controlled clinical trials. This 12-week, open-label, community-based study evaluated adapalene/BPO in 91 patients with mild to moderate acne (20-50 inflammatory lesions and 30-100 noninflammatory lesions) who were treated at dermatology centers throughout Argentina. The study evaluated efficacy, described the most common side effects, determined tolerability, and assessed the level of patient satisfaction with treatment. By week 12, there were statistically significant reductions in both inflammatory and noninflammatory lesions (80.6% and 69.3% from baseline, respectively; P < .001); there were also significant improvements in the Investigator's Global Assessment scores (median score, 2.9 at baseline and 1.0 at week 12; P < .001). By week 12, 67% of patients were rated clear or almost clear by investigators. Local tolerability was good overall. When cutaneous irritation was present, it typically occurred in the first 2 weeks of treatment and improved or resolved with continuing therapy. Patients were highly satisfied with the results of treatment, and 74% of patients felt that they had marked or total improvement by week 12. Patient survey also revealed that 94% rated the efficacy as good or very good and 87.5% rated tolerability as good or very good. A significant majority (81%) felt that the treatment met expectations, and 62% perceived that improvement had been rapid during adapalene/BPO therapy. These results demonstrate that adapalene/BPO has good efficacy and tolerability in routine practice, resulting in continuous reductions in lesion counts throughout the study. Adapalene/BPO therapy is also associated with high patient satisfaction, which is important for therapeutic adherence and satisfaction with the physician's care.
更多
查看译文
关键词
Treatment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要